Relationship between glycosylated hemoglobin A1c and coronary flow reserve in patients with Type 2 diabetes mellitus

Expert Review of Cardiovascular Therapy

Volumn 13, Issue 4, 2015, Pages 445-453

  Huang, Runqing ^a,b   Abdelmoneim, Sahar S ^a   Nhola, Lara F ^a   Basu, Rita ^a   Basu, Ananda ^a   Mulvagh, Sharon L ^a  

^a MAYO CLINIC   (United States)

^b HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

coronary flow reserve; glycemic control; glycosylated hemoglobin A1c; noninvasive techniques; Type 2 diabetes mellitus

Indexed keywords

HEMOGLOBIN A1C; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN;

ARTERIOLE; ARTERY; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CORONARY ARTERY; CORONARY FLOW RESERVE; DIABETIC ANGIOPATHY; DIABETIC PATIENT; DOPPLER ECHOCARDIOGRAPHY; GLYCEMIC CONTROL; HEART MUSCLE PERFUSION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; NON INVASIVE PROCEDURE; NONHUMAN; PATHOGENESIS; REVIEW; STENOSIS; TRANSTHORACIC ECHOCARDIOGRAPHY; COMPLICATION; CORONARY ARTERY BLOOD FLOW; CORONARY BLOOD VESSEL; DIABETIC ANGIOPATHIES; ECHOGRAPHY; HEART; METABOLISM; MICROCIRCULATION; MICROVASCULATURE; MYOCARDIAL PERFUSION IMAGING; PATHOPHYSIOLOGY; POSITRON EMISSION TOMOGRAPHY; SCINTISCANNING; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

CORONARY CIRCULATION; CORONARY VESSELS; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; ECHOCARDIOGRAPHY, DOPPLER; HEART; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; MICROCIRCULATION; MICROVESSELS; MYOCARDIAL PERFUSION IMAGING; POSITRON-EMISSION TOMOGRAPHY; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 84925304008     PISSN: 14779072     EISSN: 17448344     Source Type: Journal    
DOI: 10.1586/14779072.2015.1015992     Document Type: Review

References (49)

1. Beckman JA, Creager MA, Libby P. Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAMA 2002;287:2570-81
2. Selvin E, Crainiceanu CM, Brancati FL, et al. Short-Term variability in measures of glycemia and implications for the classification of diabetes. Arch Intern Med 2007;167:1545-51
3. UK Prospective Diabetes Study (UKPDS Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-53
4. Gerstein HC, Miller ME, Byington RP, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008;358: 2545-59
5. Duckworth W, Abraira C, Moritz T, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009;360:129-39
6. Riddle MC, Ambrosius WT, Brillon DJ, et al. Action to Control Cardiovascular Risk in Diabetes Investigators. Epidemiologic relationships between A1C and allcause mortality during a median 3.4-year follow-up of glycemic treatment in the ACCORD trial. Diabetes Care 2010;33: 983-90
7. Holman RR, Paul SK, Bethel MA, et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008;359:1577-89
8. Nathan DM, Cleary PA, Backlund JY, et al Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005;353:2643-53
9. Gahz W, Tamura K, Marcus HS, et al. Measurements of coronary sinus blood flow by continuous thermodilution in man. Circulation 1971;44:181-9
10. Nitenberg A, Valensi P, Sachs R, et al. Impairment of coronary vascular reserve and ach-induced coronary vasodilation in diabetic patients with angiographically normal coronary arteries and normal left ventricular systolic function. Diabetes 1993;42:1017-25
11. Bakker W, Eringa EC, Sipkema P, et al. Endothelial dysfunction and diabetes: roles of hyperglycemia, impaired insulin signaling and obesity. Cell Tissue Res 2009;335: 165-89
12. Kaneto H, Katakami N, Matsuhisa M, et al. Role of reactive oxygen species in the progression of type 2 diabetes and atherosclerosis. Mediators Inflamm 2010;2010:453892
13. Feng L, Matsumoto C, Schwartz A, et al. Chronic vascular inflammation in patients with type 2 diabetes: endothelial biopsy and RT-PCR analysis. Diabetes Care 2005;28: 379-84
14. Gao X, Zhang H, Schmidt AM, et al. AGE/RAGE produces endothelial dysfunction in coronary arterioles in type 2 diabetic mice. Am J Physiol Heart Circ Physiol 2008;295:H491-8
15. Feng J, Chu LM, Dobrilovic N, et al. Decreased coronary microvascular reactivity after cardioplegic arrest in patients with uncontrolled diabetes mellitus. Surgery 2012;152:262-9
16. Cosentino F, Eto M, De Paolis P, et al. High glucose causes upregulation of cyclooxygenase-2 and altered prostanoid profile in human endothelial cells. Role of protein kinase C and reactive oxygen species. Circulation 2003;107:1017-23
17. Aronson D, Rayfield EJ. How hyperglycaemia promotes atherosclerosis: molecular mechanisms. Cardiovasc Diabetol 2002;1:1
18. He Z, King GL. Microvascular complications of diabetes. Endocrinol Metab Clin North Am 2004;33:215-38 xi-xii
19. Kanatsuka H, Lamping KG, Eastham CL, et al. Comparison of the effects of increased myocardial oxygen consumption and adenosine on the coronary microvascular resistance. Circ Res 1989;65:1296-305
20. Patel B, Fisher M. Therapeutic advances in myocardial microvascular resistance: unravelling the enigma. Pharmacol Ther 2010;127:131-47
21. Camici PG, Crea F. Coronary microvascular dysfunction. N Engl J Med 2007;356: 830-40
22. Kuo L, Davis MJ, Chilian WM. Longitudinal gradients for endothelium-dependent and -independent vascular responses in the coronary circulation. Circulation 1995;92:518-25
23. Kuo L, Davis MJ, Chilian WM. Endothelial modulation of arteriolar tone. News Physiol Sci 1992;7:5-9
24. Strauer BE, Motz W, Vogt M, et al. Impaired coronary flow reserve in NIDDM: a possible role for diabetic cardiopathy in humans. Diabetes 1997;46(Suppl 2): S119-24
25. Fein FS, Sonnenblick EH. Diabetic cardiomyopathy. Cardiovasc Drugs Ther 1994;8:65-73
26. De Vriese AS, Verbeuren TJ, Van De Voorde J, et al. Endothelial dysfunction in diabetes. Br J Pharmacol 2000;130:963-74
27. Erdös B, Miller AW, Busija DW. Impaired endothelium mediated relaxation in isolated cerebral arteries from insulin resistant rats. Am J Physiol Heart Circ Physiol 2002;282: H2060-5
28. Sjögren A, Edvinsson L. Vasomotor changes in isolated coronary arteries from diabetic rats. Acta Physiol Scand 1988;134:429-36
29. Nitenberg A, Paycha F, Ledoux S, et al. Coronary artery responses to physiological stimuli are improved by deferoxamine but not by L-arginine in noninsulin- dependent diabetic patients with angiographically normal coronary arteries and no other risk factors. Circulation 1998;97:736-43
30. Ammar RF Jr, Gutterman DD, Brooks LA, et al. Impaired dilation of coronary arterioles during increases in myocardial O (2) consumption with hyperglycemia. Am J Physiol Endocrinol Metab 2000;279: E868-74
31. Rigo F. Coronary flow reserve in stress-echo lab. From pathophysiologic toy to diagnostic tool. Cardiovasc Ultrasound 2005;3:8-19
32. Erdogan D, Yucel H, Uysal BA, et al. Effects of prediabetes and diabetes on left ventricular and coronary microvascular functions. Metabolism 2013;62:1123-30
33. Yuksel Kalkan G, Gur M, Eksi Haydardedeoʇlu F, et al. The Association between Aortic Distensibility and Coronary Flow Reserve in Newly Diagnosed Diabetic Patients. Echocardiography 2014;12:1-8
34. Kawata T, Daimon M, Hasegawa R, et al. Prognostic value of coronary flow reserve assessed by transthoracic Doppler echocardiography on long-Term outcome in asymptomatic patients with type 2 diabetes without overt coronary artery disease. Cardiovasc Diabetol 2013;12:121
35. Cortigiani L, Rigo F, Gherardi S, et al. Additional prognostic value of coronary flow reserve in diabetic and nondiabetic patients with negative dipyridamole stress echocardiography by wall motion criteria. J Am Coll Cardiol 2007;50:1354-61
36. Wei Z, Zhang H, Su H, et al. Correlation between myocardial dysfunction and perfusion impairment in diabetic rats with velocity vector imaging and myocardial contrast echocardiography. Echocardiography 2012;29:1247-55
37. Abdelmoneim SS, Basu A, Bernier M, et al. Detection of myocardial microvascular disease using contrast echocardiography during adenosine stress in type 2 diabetes mellitus: prospective comparison with single-photon emission computed tomography. Diab Vasc Dis Res 2011;8: 254-61
38. Huang R, Abdelmoneim SS, Nhola LF, et al. Relationship between HgbA1c and myocardial blood flow reserve in patients with Type 2 diabetes mellitus: noninvasive assessment using Real-Time myocardial perfusion echocardiography. J Diabetes Res 2014;2014:243518
39. Abdelmoneim SS, Hagen ME, Mendrick E, et al. Acute hyperglycemia reduces myocardial blood flow reserve and the magnitude of reduction is associated with insulin resistance: a study in nondiabetic humans using contrast echocardiography. Heart Vessels 2013;28:757-68
40. Alexanderson E, Rodriguez-Valero M, Martinez A, et al. Endothelial dysfunction in recently diagnosed type 2 diabetic patients evaluated by PET. Mol Imaging Biol 2009;11:1-5
41. Murthy VL, Naya M, Foster CR, et al. Association between coronary vascular dysfunction and cardiac mortality in patients with and without diabetes mellitus. Circulation 2012;126:1858-68
42. Sultan A, Piot C, Mariano-Goulart D, et al. Myocardial perfusion imaging and cardiac events in a cohort of asymptomatic patients with diabetes living in southern France. Diabet Med 2006;23:410-18
43. Wackers FJ, Young LH, Inzucchi SE, et al. Detection of Ischemia in Asymptomatic Diabetics Investigators. Detection of silent myocardial ischemia in asymptomatic diabetic subject. Diabetes Care 2004;27: 1954-61
44. Lynn Fillipon NM, Kitkungvan D, Dani SS, et al. The Relationship Between Glycosylated Hemoglobin and Myocardial Perfusion Imaging. Clin Cardiol 2012;35:565-9
45. Fatima N, u Zaman M, Ishaq M, et al. Impact of glycosylated hemoglobin (HBA1C) on the extent of perfusion abnormalities and left ventricular dysfunction using gated myocardial perfusion imaging and clinical outcomes in diabetic patients. Nucl Med Commun 2013;34:489-94
46. Yu J, Zhang Z, Li Z, et al. Peroxisome proliferator-activated receptor-gamma (PPARgamma) agonist improves coronary artery endothelial function in diabetic patients with coronary artery disease. J Int Med Res 2010;38:86-94
47. McMahon GT, Plutzky J, Daher E, et al. Effect of a peroxisome proliferator-activated receptor-gamma agonist on myocardial blood flow in type 2 diabetes. Diabetes Care 2005;28:1145-50
48. Dluhy RG, McMahon GT. Intensive glycemic control in the ACCORD and ADVANCE trials. N Engl J Med 2008;358: 2630-3
49. Factor SM, Minase T, Cho S, et al. Coronary microvascular abnormalities in the hypertensive-diabetic rat. A primary cause of cardiomyopathy?. Am J Pathol 1984;116: 9-20.